The development of the tumor vascular-disrupting agent ASA404 (vadimezan, DMXAA): current status and future opportunities

By Head Michelle   Jameson Michael B  

Expert Opinion on Investigational Drugs, Vol. 19, Iss. 2, 2010-02 ,pp. : 295-304

Informa Healthcare

Access to resources Recommend Favorite

Enhancement of the action of the antivascular drug 5,6-dimethylxanthenone-4-acetic acid (DMXAA; ASA404) by non-steroidal anti-inflammatory drugs

By Wang L.-C.   Ching Lai-Ming   Paxton James   Kestell Philip   Sutherland Rachel   Zhuang Li   Baguley Bruce  

Investigational New Drugs, Vol. 27, Iss. 3, 2009-06 ,pp. : 280-284

Springer Publishing Company

Access to resources Recommend Favorite

Temporal aspects of the action of ASA404 (vadimezan; DMXAA)

By Baguley Bruce C   Siemann Dietmar W  

Expert Opinion on Investigational Drugs, Vol. 19, Iss. 11, 2010-11 ,pp. : 1413-1425

Informa Healthcare

Access to resources Recommend Favorite

Clinical pharmacology in drug development — an update

By  

Clinical Pharmacology In Drug Development, Vol. 4, Iss. 4, 2015-07 ,pp. : 243-244

John Wiley & Sons Inc

Access to resources Recommend Favorite

The potential of DMXAA (ASA404) in combination with docetaxel in advanced prostate cancer

By McKeage Mark J  

Expert Opinion on Investigational Drugs, Vol. 17, Iss. 1, 2008-01 ,pp. : 23-29

Informa Healthcare

Access to resources Recommend Favorite